# PD-1 Monoclonal Antibody Combined With Gemcitabine and Cisplatin Followed by Selective Radiotherapy for Unresectable Locally Recurrent NPC

> **NCT07528183** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 86 (estimated)

## Conditions studied

- Nasopharyngeal Cancinoma (NPC)

## Interventions

- **DRUG:** PD-1 monoclonal antibody combined with gemcitabine and cisplatin followed by selective radiotherapy

## Key facts

- **NCT ID:** NCT07528183
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-10
- **Primary completion:** 2032-04-10
- **Final completion:** 2035-04-10
- **Target enrollment:** 86 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07528183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07528183, "PD-1 Monoclonal Antibody Combined With Gemcitabine and Cisplatin Followed by Selective Radiotherapy for Unresectable Locally Recurrent NPC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07528183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*